Celltrion said Tuesday that its flagship autoimmune treatment Remsima has consolidated its leadership in Europe, with the product lineup capturing a 68 percent market share in the third quarter of last year.

Citing data from pharmaceutical market research firm IQ

πŸ“°

Continue Reading on The Korea Herald

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article β†’